Catalog No.: PC-20590Not For Human Use, Lab Use Only.
Alpelisib (NVP-BYL719, BYL719) is ia potent, selective, and orally active PI3Kα inhibitor with IC50 of 5 nM, >50-fold selectivity over p110γ/p110δ/p110β.
Alpelisib (NVP-BYL719, BYL719) is ia potent, selective, and orally active PI3Kα inhibitor with IC50 of 5 nM, >50-fold selectivity over p110γ/p110δ/p110β.
Alpelisib (BYL719) potently inhibits PIK3CA somatic mutations (H1047R, E545K) with IC50 of 4 nM.
Alpelisib (BYL719) potently inhibits Akt phosphorylation in cells transformed with PI3Kα (IC50=74 nM) and shows significant reduced inhibitory activity in PI3Kβ or PI3Kδ isoforms transformed cells (>15-fold).
Alpelisib (BYL719) (0-50 uM) inhibits the cell growth of osteosarcoma cell lines MG63, HOS, POS-1 and MOS-J in a dose-dependent manner.
Alpelisib (BYL719) potently suppresses proliferation and PI3K signaling in human breast cancer cells harboring PIK3CA(H1047R) in combination with lapatinib.
Alpelisib (BYL719) inhibits growth factor-independent KRASG12D BM colony formation and sensitizes cells to a low dose of the MEK inhibitor MEK162.
